Supriya Lifescience gets provisional release of 200kg Ketamine HCl consignment
Supriya Lifescience Limited's application for provisional release of 200 kg Ketamine Hydrochloride consignment has been allowed by the Hon'ble High Court of Bombay. The release is conditional upon a ₹72 lakh deposit within a week. Adjudication and criminal proceedings can continue.
The provisional release of a significant consignment is positive, but the requirement to deposit ₹72 lakh and the continuation of legal proceedings indicate a medium impact.
The court's decision to allow the provisional release of the consignment is a positive development for the company, even with the condition of depositing funds.
Supriya Lifescience Limited has received a significant update regarding its application for the provisional release of a consignment of 200 kg of Ketamine Hydrochloride. The Hon'ble High Court of Bombay, in its judgment dated September 22, 2026, allowed the company's application.
This provisional release is subject to the company depositing ₹72 lakh with the Assistant Commissioner of Customs, Export, ACC, Mumbai -III within one week from the date of the order. The court has also clarified that authorities can continue with adjudication and criminal proceedings as per law, and it shall be open to the concerned officer to follow procedures under Section 52A of the NDPS Act.
The company had previously submitted letters on July 4, 2026, and September 2, 2026, concerning this matter. Supriya Lifescience Limited will continue to monitor the situation and will inform the stock exchanges of any further developments.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.